University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 10 of 35
LetSync: Pilot Test of Mobile Health (mHealth) Intervention
NCT04951544
Accuracy of Ultrasound for Detecting Residual Fragments During RIRS
NCT05535816
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
NCT05695898
HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
NCT05708976
Translating Anesthesia Care Throughout
NCT05502029
COVID-19 Pandemic Induced Stress and Symptoms
NCT06036251
Youth Ending the HIV Epidemic
NCT05789875
Excipient Effect on Drug Absorption in Humans
NCT04534153
The Care Ecosystem Consortium Effectiveness Study
NCT05669365
The Brain Health Study: A Pragmatic, Patient-Centered Trial
NCT05905796
The OPENS Trial: Offering Women PrEP (Aim 2)
NCT05619497
Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
NCT05288023
Interactive Mobile Doctor (iMD) to Promote Tobacco Cessation Among Cancer Patients
NCT05021185
Micronutrient Supplementation in Children With ASD
NCT05268744
Black Economic Equity Movement
NCT05609188
Impact of Music Improvisation Training on Cognitive Function in Older Adults
NCT05980286
Evaluating the Feasibility of VR for Pediatric Renal Biopsies
NCT05267704
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
NCT05273385
Facilitating COVID-19 Test for Korean Americans Through Korean Schools in Northern California
NCT05435482
PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED
NCT05836818
Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
NCT05391555
Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy
NCT05342675
HIV Prevention Peer Navigation for Justice Involved Women
NCT04680390
Remote School-Home Program to Improve Youth Attention and Behavior in Mexican Students
NCT05496140
Pulse Oximetry Errors in Hospitalized Patients Across Varying Skin Pigmentation
NCT05554510
Optimizing Provider Training in Eating Disorders (OPTED)
NCT05389657
Decision Making for Older Adults With Cancer
NCT05374304
Lupus Walking Intervention to Address Fatigue/Quality of Life
NCT07481214
Remote Cognitive Assessment for Surgical Patients
NCT05566275
Investigation of Pupillometry as Guide for Extubation Readiness in Anesthetized Children
NCT04947397
Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)
NCT05152953
Examine the Effects of Mindfulness in Woman With a History of Child Adversity
NCT05255380
Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures
NCT05294640
Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use
NCT04404075
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
NCT05169944
Intralesional HPV Vaccine for Condylomata
NCT05087849
Induced Pluripotent Stem Cells for Disease Research
NCT04476225
Hypertension in Young Adults Trial
NCT05370599
The Heart Rhythm Twins Study
NCT05866731
MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer
NCT05127850
Lemborexant Shift Work Treatment Study
NCT05344443
Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
NCT05324098
Attachment and Biobehavioral Catch-up and Depression Treatment
NCT05096611
Australian University of California San Francisco (UCSF) Concussion in Athletes (AUSSIE-2)
NCT05771051
Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
NCT05102474
Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION)
NCT05217849
Pilot Trial of a Game Embedded in a Smartphone App for Smoking Cessation
NCT05227027
A Silver Lining in the VAD Sky
NCT05163392
Smoke-free Home Intervention in Permanent Supportive Housing
NCT04855357
The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)
NCT05268185
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.